Stockreport

Sanofi/Regeneron's Dupixent set to dominate COPD biologics market following FDA approval [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron's interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US ma [Read more]